[go: up one dir, main page]

EA201001596A1 - Соединения и композиции в качестве ингибиторов протеинкиназы - Google Patents

Соединения и композиции в качестве ингибиторов протеинкиназы

Info

Publication number
EA201001596A1
EA201001596A1 EA201001596A EA201001596A EA201001596A1 EA 201001596 A1 EA201001596 A1 EA 201001596A1 EA 201001596 A EA201001596 A EA 201001596A EA 201001596 A EA201001596 A EA 201001596A EA 201001596 A1 EA201001596 A1 EA 201001596A1
Authority
EA
Eurasian Patent Office
Prior art keywords
compounds
compositions
ros
proteinkinase inhibitors
proteinkinase
Prior art date
Application number
EA201001596A
Other languages
English (en)
Other versions
EA018484B1 (ru
Inventor
Тао Цзян
Пьерр-Ив Мишелли
Трук Нгок Нгуйен
Вэй Пэй
Баогэнь Ву
Сюфэн Чжу
Original Assignee
Айрм Ллк
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Айрм Ллк filed Critical Айрм Ллк
Publication of EA201001596A1 publication Critical patent/EA201001596A1/ru
Publication of EA018484B1 publication Critical patent/EA018484B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Настоящее изобретение относится к новым производным триазина и пиримидина формул (1) или (2) и к способам применения таких соединений. Например, соединения по изобретению могут использоваться для лечения, облегчения или профилактики состояния, которое связано с ингибированием активности анапластической лимфомной киназы (ALK), онкогена c-ros (ROS), инсулиноподобного фактора роста (IGF-1R) и/или инсулинового рецептора (InsR) или их комбинации.
EA201001596A 2008-04-07 2009-04-03 Соединения и композиции в качестве ингибиторов протеинкиназы EA018484B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4311108P 2008-04-07 2008-04-07
US9588308P 2008-09-10 2008-09-10
PCT/US2009/039380 WO2009126514A1 (en) 2008-04-07 2009-04-03 Compounds and compositions as kinase inhibitors

Publications (2)

Publication Number Publication Date
EA201001596A1 true EA201001596A1 (ru) 2011-04-29
EA018484B1 EA018484B1 (ru) 2013-08-30

Family

ID=40786670

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201001596A EA018484B1 (ru) 2008-04-07 2009-04-03 Соединения и композиции в качестве ингибиторов протеинкиназы

Country Status (13)

Country Link
US (1) US8518931B2 (ru)
EP (1) EP2271645A1 (ru)
JP (1) JP5214799B2 (ru)
KR (1) KR20110002080A (ru)
CN (1) CN102056925A (ru)
AR (1) AR071300A1 (ru)
AU (1) AU2009233963B2 (ru)
BR (1) BRPI0910979A2 (ru)
CA (1) CA2720944C (ru)
EA (1) EA018484B1 (ru)
MX (1) MX2010011069A (ru)
UY (1) UY31750A (ru)
WO (1) WO2009126514A1 (ru)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI389893B (zh) 2007-07-06 2013-03-21 Astellas Pharma Inc 二（芳胺基）芳基化合物
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
EP3210609A1 (en) 2008-05-21 2017-08-30 Ariad Pharmaceuticals, Inc. Phosphorous derivatives as kinase inhibitors
CA2760061C (en) 2009-05-08 2017-02-28 Astellas Pharma Inc. Diamino heterocyclic carboxamide compound
WO2012097478A1 (en) * 2011-01-21 2012-07-26 Abbott Laboratories Bicyclic carboxamide inhibitors of kinases
CA2832504C (en) 2011-05-04 2019-10-01 Ariad Pharmaceuticals, Inc. Compounds for inhibiting cell proliferation in egfr-driven cancers
AU2013204563B2 (en) 2012-05-05 2016-05-19 Takeda Pharmaceutical Company Limited Compounds for inhibiting cell proliferation in EGFR-driven cancers
US9353107B2 (en) 2012-07-03 2016-05-31 Aurigene Discovery Technologies Limited 3-(pyrazolyl)-1H-pyrrolo[2,3-b]pyridine derivatives as kinase inhibitors
JP6359020B6 (ja) * 2012-11-06 2018-08-15 シャンハイ フォチョン ファーマシューティカル カンパニー リミテッド Ａｌｋキナーゼ阻害剤
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
CN103570728B (zh) * 2013-11-12 2015-12-30 山东大学 一种取代吡唑并[1,5-a]嘧啶类衍生物及其制备方法与应用
US10280170B2 (en) * 2014-03-27 2019-05-07 Janssen Pharmaceutica Nv Substituted 4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyrazine derivatives and 5,6,7,8-tetrahydro-4H-pyrazolo[1,5-a][1,4]diazepine derivatives as Ros1 inhibitors
EP3256475A4 (en) * 2015-02-13 2019-02-13 Dana-Farber Cancer Institute, Inc. LRRK2 INHIBITORS AND METHOD FOR THE PRODUCTION AND USE THEREOF
CN117946114A (zh) 2017-07-28 2024-04-30 武田药品工业株式会社 Tyk2抑制剂与其用途
CN110483526B (zh) * 2019-09-09 2021-10-01 辽宁大学 含芳基腙结构的吡唑并[1,5-a]嘧啶类衍生物及其应用
GB201915618D0 (en) 2019-10-28 2019-12-11 Univ Oslo ALK inhibitors for treatment of ALK-negative cancer and antibody-mediated diseases

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7406641A (ru) 1973-05-22 1974-11-26
WO2002050079A1 (fr) 2000-12-20 2002-06-27 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Inhibiteurs de kinases dependantes des cylines (cdk) et de la glycogene synthase kinase-3 (gsk-3)
FR2842809A1 (fr) * 2002-07-26 2004-01-30 Greenpharma Sas NOUVELLES PYRAZOLO[1,5-a]-1,3,5-TRIAZINES SUBSTITUEES ET LEURS ANALOGUES, COMPOSITIONS PHARMACEUTIQUES LES CONTENANT, UTILISATION A TITRE DE MEDICAMENT ET PROCEDES POUR LEUR PREPARATION
KR20050033659A (ko) * 2002-09-04 2005-04-12 쉐링 코포레이션 사이클린 의존성 키나제 억제제로서의 피라졸로[1,5-ａ]피리미딘 화합물
AU2004215481B2 (en) * 2003-02-28 2010-11-11 Teijin Pharma Limited Pyrazolo(1,5-A)pyrimidine derivatives
GB0305559D0 (en) * 2003-03-11 2003-04-16 Teijin Ltd Compounds
WO2004087707A1 (en) * 2003-03-31 2004-10-14 Vernalis (Cambridge) Limited Pyrazolopyrimidine compounds and their use in medicine
US20070060595A1 (en) * 2003-10-10 2007-03-15 Toshio Yoshizawa Novel fused heterocyclic compound and use thereof
TW200536536A (en) * 2004-02-25 2005-11-16 Schering Corp Pyrazolotriazines as kinase inhibitors
JP2006160628A (ja) * 2004-12-03 2006-06-22 Ishihara Sangyo Kaisha Ltd アデノシンＡ２ａ受容体アゴニストの投与が必要な疾患を治療又は予防するための組成物
JP2008524330A (ja) * 2004-12-21 2008-07-10 シェーリング コーポレイション ピラゾロ［１，５−Ａ］ピリミジンアデノシンＡ２ａ受容体アンタゴニスト
US7723336B2 (en) * 2005-09-22 2010-05-25 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
US7517882B2 (en) * 2006-09-18 2009-04-14 Polaris Group Protein kinase inhibitors
WO2008057402A2 (en) 2006-11-02 2008-05-15 Cytovia, Inc. N-aryl-isoxazolopyrimidin-4-amines and related compounds as activators of caspases and inducers of apoptosis and the use thereof

Also Published As

Publication number Publication date
US8518931B2 (en) 2013-08-27
BRPI0910979A2 (pt) 2016-01-05
US20110190264A1 (en) 2011-08-04
UY31750A (es) 2009-12-14
AU2009233963A1 (en) 2009-10-15
AU2009233963B2 (en) 2011-10-06
CA2720944C (en) 2012-12-18
JP2011516554A (ja) 2011-05-26
AR071300A1 (es) 2010-06-09
WO2009126514A1 (en) 2009-10-15
CN102056925A (zh) 2011-05-11
JP5214799B2 (ja) 2013-06-19
MX2010011069A (es) 2010-11-12
WO2009126514A8 (en) 2010-10-21
EA018484B1 (ru) 2013-08-30
EP2271645A1 (en) 2011-01-12
CA2720944A1 (en) 2009-10-15
KR20110002080A (ko) 2011-01-06

Similar Documents

Publication Publication Date Title
EA201001596A1 (ru) Соединения и композиции в качестве ингибиторов протеинкиназы
EA201001597A1 (ru) Соединения и композиции в качестве ингибиторов протеинкиназы
EA201100077A1 (ru) Производные пиримидина в качестве ингибиторов киназы
MX2010002336A (es) Derivados de 2-bifenil-amino-4-amino-pirimidina como inhibidores de cinasa.
EA201100078A1 (ru) Производные пиримидина в качестве ингибиторов киназы
EA200970557A1 (ru) Соединения и композиции в качестве ингибиторов протеинкиназы
UA100846C2 (ru) Соединения и композиция как ингибиторы протеинкиназы
TW200718693A (en) Aminopyrimidines as kinase modulators
WO2012017239A3 (en) 4-(1h-indol-3-yl) -pyrimidines as alk inhibitors
TW200716118A (en) Aminopyrimidines as kinase modulators
MX2010009207A (es) Compuestos y composiciones heterociclicos como inhibidores de c-kit y pdgfr cinasa.
MY153727A (en) Pyridazinone derivatives
GEP20135785B (en) Pyrrolopyrimidine compounds as cdk inhibitors
TW200716598A (en) Aminoquinoline and aminoquinazoline kinase modulators
EA201100580A1 (ru) Имидазопиридазинкарбонитрилы, используемые в качестве ингибиторов киназы
MX367158B (es) Benzotienilo-pirrolotriazinas disustituidas y su uso como inhibidores de quinasa fgfr.
MX2009011950A (es) Derivados de pirimidina y composiciones como inhibidores de cinasa c-kit y pdgfr.
TW200716599A (en) Alkylquinoline and alkylquinazoline kinase modulators
MY155719A (en) 2-benzylpyridazinone derivatives as met kinase inhibitors
MX2013007702A (es) Compuestos heterociclicos y su uso como inhibidores de la cinasa 3 de glucogeno sintasa.
MX2011007165A (es) Derivados de piridazinona.
MX2009012079A (es) Compuestos heterociclicos condensados como inhibidores de proteina cinasas.
MX2010002096A (es) Derivados de tiadiazinona.
MX2011007209A (es) Derivados de piridazinona.
TN2010000602A1 (en) Pyrimidine derivatives as kinase inhibitors

Legal Events

Date Code Title Description
MC4A Revocation of a eurasian patent under opposition procedure

Designated state(s): AM AZ BY KZ KG MD TJ TM RU